SG11201404776PA - Combination of muscarinic receptor antagonists and beta- 3 adrenoceptor agonists for treating overactive bladder - Google Patents
Combination of muscarinic receptor antagonists and beta- 3 adrenoceptor agonists for treating overactive bladderInfo
- Publication number
- SG11201404776PA SG11201404776PA SG11201404776PA SG11201404776PA SG11201404776PA SG 11201404776P A SG11201404776P A SG 11201404776PA SG 11201404776P A SG11201404776P A SG 11201404776PA SG 11201404776P A SG11201404776P A SG 11201404776PA SG 11201404776P A SG11201404776P A SG 11201404776PA
- Authority
- SG
- Singapore
- Prior art keywords
- beta
- combination
- receptor antagonists
- muscarinic receptor
- overactive bladder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261596893P | 2012-02-09 | 2012-02-09 | |
| PCT/US2013/025285 WO2013119910A1 (en) | 2012-02-09 | 2013-02-08 | Combination of muscarinic receptor antagonists and beta- 3 adrenoceptor agonists for treating overactive bladder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201404776PA true SG11201404776PA (en) | 2014-09-26 |
Family
ID=48948043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201404776PA SG11201404776PA (en) | 2012-02-09 | 2013-02-08 | Combination of muscarinic receptor antagonists and beta- 3 adrenoceptor agonists for treating overactive bladder |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP2811989A1 (en) |
| JP (1) | JP2015509931A (en) |
| KR (1) | KR20150020160A (en) |
| CN (1) | CN104684549A (en) |
| AR (1) | AR089957A1 (en) |
| AU (1) | AU2013216864A1 (en) |
| CA (1) | CA2864173A1 (en) |
| HK (1) | HK1204966A1 (en) |
| IL (1) | IL234033A0 (en) |
| PH (1) | PH12014501814A1 (en) |
| SG (1) | SG11201404776PA (en) |
| TW (1) | TW201338772A (en) |
| WO (1) | WO2013119910A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
| US9522129B2 (en) | 2010-08-03 | 2016-12-20 | Velicept Therapeutics, Inc. | Pharmaceutical Combination |
| KR20170086659A (en) | 2014-12-03 | 2017-07-26 | 벨리셉트 테라퓨틱스, 인크. | Compositions and methods of using modified release solabegron for lower urinary tract symptoms |
| FI3365321T3 (en) | 2015-10-23 | 2024-01-02 | B3Ar Therapeutics Inc | Solabegron zwitterion and uses thereof |
| KR101868438B1 (en) | 2017-04-13 | 2018-06-20 | (주) 성운파마코피아 | Method for preparing amide derivatives |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL267508A (en) | 1960-07-26 | |||
| US5677346A (en) | 1995-01-31 | 1997-10-14 | Sepracor, Inc. | Treating urinary incontinence using (S)-desethyloxybutynin |
| US6123961A (en) | 1996-09-25 | 2000-09-26 | Bridge Pharma, Inc. | Treating urinary incontinence with (R)-desethyloxybutynin and (R)-oxybutynin |
| GB9812709D0 (en) | 1998-06-13 | 1998-08-12 | Glaxo Group Ltd | Chemical compounds |
| GB9929297D0 (en) | 1999-12-11 | 2000-02-02 | Glaxo Group Ltd | Process |
| GB0102407D0 (en) | 2001-01-31 | 2001-03-14 | Glaxo Group Ltd | Process |
| TW200800953A (en) * | 2002-10-30 | 2008-01-01 | Theravance Inc | Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine |
| EP1424079A1 (en) * | 2002-11-27 | 2004-06-02 | Boehringer Ingelheim International GmbH | Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine |
| EP2141992A1 (en) * | 2007-03-29 | 2010-01-13 | Merck & Co., Inc. | Combination therapy for the treatment-of lower urinary tract symptoms |
| PE20091825A1 (en) | 2008-04-04 | 2009-12-04 | Merck & Co Inc | HYDROXIMETHYL PYRROLIDINES AS AGONISTS OF THE BETA 3 ADRENERGIC RECEPTOR |
| US8354403B2 (en) | 2009-08-27 | 2013-01-15 | Merck Sharp & Dohme Corp. | Pyrrolidine derived beta 3 adrenergic receptor agonists |
| JP5738871B2 (en) * | 2009-10-07 | 2015-06-24 | メルク・シャープ・エンド・ドーム・コーポレイション | Combination therapy with β3 adrenergic receptor agonist and antimuscarinic agent |
-
2013
- 2013-02-08 CN CN201380019041.9A patent/CN104684549A/en active Pending
- 2013-02-08 WO PCT/US2013/025285 patent/WO2013119910A1/en active Application Filing
- 2013-02-08 AR ARP130100415A patent/AR089957A1/en unknown
- 2013-02-08 CA CA2864173A patent/CA2864173A1/en not_active Abandoned
- 2013-02-08 KR KR20147023969A patent/KR20150020160A/en not_active Application Discontinuation
- 2013-02-08 SG SG11201404776PA patent/SG11201404776PA/en unknown
- 2013-02-08 JP JP2014556709A patent/JP2015509931A/en active Pending
- 2013-02-08 EP EP13704702.3A patent/EP2811989A1/en not_active Withdrawn
- 2013-02-08 TW TW102105243A patent/TW201338772A/en unknown
- 2013-02-08 AU AU2013216864A patent/AU2013216864A1/en not_active Abandoned
-
2014
- 2014-08-10 IL IL234033A patent/IL234033A0/en unknown
- 2014-08-11 PH PH12014501814A patent/PH12014501814A1/en unknown
-
2015
- 2015-06-17 HK HK15105751.1A patent/HK1204966A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2811989A1 (en) | 2014-12-17 |
| CN104684549A (en) | 2015-06-03 |
| AR089957A1 (en) | 2014-10-01 |
| HK1204966A1 (en) | 2015-12-11 |
| IL234033A0 (en) | 2014-09-30 |
| AU2013216864A1 (en) | 2014-09-11 |
| WO2013119910A1 (en) | 2013-08-15 |
| CA2864173A1 (en) | 2013-08-15 |
| PH12014501814A1 (en) | 2014-11-24 |
| KR20150020160A (en) | 2015-02-25 |
| TW201338772A (en) | 2013-10-01 |
| JP2015509931A (en) | 2015-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL267066B (en) | Activin-actrii antagonists and uses for treating bone and other disorders | |
| HRP20180915T1 (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| EP2841154A4 (en) | Bladder tissue modification for overactive bladder disorders | |
| SG10201506076TA (en) | Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder | |
| HRP20151103T1 (en) | Substituted triazolopyridines and their use as ttk inhibitors | |
| EP2680853A4 (en) | Treatment of cancer with dopamine receptor antagonists | |
| PL2928890T3 (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| AP2014008011A0 (en) | Agents for treating disorders involving modulationof ryanodine receptors | |
| EP2709991A4 (en) | Use of cxcr4 antagonists | |
| IL238665A0 (en) | Composition for permanently hydrophilizing polyolefin fibers and use thereof | |
| HK1204966A1 (en) | Combination of muscarinic receptor antagonists and beta- 3 adrenoceptor agonists for treating overactive bladder -3 | |
| PL2682103T3 (en) | Compositions Comprising Muscarinic Receptor Antagonist and Sorbitol | |
| HK1202459A1 (en) | Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders | |
| IL237150B (en) | Compositions comprising combinations of receptor agonists and receptor antagonists | |
| EP2862577A4 (en) | Use of obestatin for muscle regeneration | |
| IL238120B (en) | Combination of adrenalin with an antidepressant for use in the treatment of shock | |
| PT2709991T (en) | Use of cxcr4 antagonists | |
| PL395618A1 (en) | Device for enhancing stability of muscle fibers |